Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of topical CLS003 for HPV-induced genital lesions
NL-OMON46258Phase 2Active, not recruiting
- Sponsor
- Biofrontera
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of digoxin and furosemide in anogenital warts and vulvar intraepithelial neoplasia (VIN) (2 arms), sponsored by Biofrontera. Primary endpoints: Lesion size reduction, Patient-reported outcomes and 14 more. Started Sep 2017; status: active, not recruiting.
02
Drugs
digoxinfurosemide
03
Conditions
anogenital wartsvulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on NL-OMON46258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46258.